Who
Philip J. Vickers
Director
Company insider
Files Form 4 as: Director, Akebia Therapeutics; Director, Tectonic Therapeutic; Director, Revance Therapeutics.
In numbers
- Trades disclosed
- 28
- Buys
- 2
- Sells
- 0
- Bought
- $138K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 26 Feb 2015
- Last trade
- 1 Apr 2026
- Last filed
- 3 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Apr 2026filed 3 Apr 2026 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —214,400 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —214,400 at $0.00 | filing |
| 6 Jun 2023filed 8 Jun 2023 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,643 at $0.00 | filing |
| 8 Jun 2022filed 10 Jun 2022 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,478 at $0.00 | filing |
| 8 Jun 2022filed 10 Jun 2022 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,478 at $0.00 | filing |
| 4 May 2022filed 13 May 2022 | Revance Therapeuticsoption or derivative | SEC FORM 4 Code A | —10,756 at $0.00 | filing |
| 4 May 2022filed 6 May 2022 | Revance Therapeuticsoption or derivative | SEC FORM 4 Code A | —11,343 at $0.00 | filing |
| 4 May 2022filed 6 May 2022 | Revance Therapeutics | SEC FORM 4 Code A | —6,059 at $0.00 | filing |
| 7 Jul 2021filed 8 Jul 2021 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Bought | $40K4,800 at $8.35 | filing |
| 10 Jun 2021filed 14 Jun 2021 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,438 at $0.00 | filing |
| 5 May 2021filed 7 May 2021 | Revance Therapeutics | SEC FORM 4 Code A | —4,013 at $0.00 | filing |
| 5 May 2021filed 7 May 2021 | Revance Therapeuticsoption or derivative | SEC FORM 4 Code A | —7,551 at $0.00 | filing |
| 4 Jun 2020filed 5 Jun 2020 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 14 May 2020filed 15 May 2020 | Revance Therapeuticsoption or derivative | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 14 May 2020filed 15 May 2020 | Revance Therapeutics | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 11 Jun 2019filed 13 Jun 2019 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,675 at $0.00 | filing |
| 9 May 2019filed 10 May 2019 | Revance Therapeuticsoption or derivative | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 9 May 2019filed 10 May 2019 | Revance Therapeutics | SEC FORM 4 Code A | —4,500 at $0.00 | filing |
| 7 Jan 2019filed 9 Jan 2019 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,743 at $0.00 | filing |
| 10 May 2018filed 11 May 2018 | Revance Therapeutics | SEC FORM 4 Code A | —3,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.